MIR3180-3: A Potential Drug Target and Biomarker (G100422836)
MIR3180-3: A Potential Drug Target and Biomarker
Mir3180-3, a nuclear transmembrane protein located in the endoplasmic reticulum, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies, which could lead to new therapeutic approaches for these diseases.
The MIR3180-3 protein is composed of 156 amino acids and has a calculated molecular weight of 19.9 kDa. It is expressed in most tissues and cells and is predominantly localized to the endoplasmic reticulum, where it functions as a transmembrane protein. MIR3180-3 is involved in various cellular processes, including protein folding, localization, and degradation.
MIR3180-3 has been shown to play a crucial role in the regulation of endoplasmic reticulum (ER) traffic, which is responsible for the delivery of proteins to the plasma membrane for secretion and protein synthesis. MIR3180-3 is a key regulator of the ER protein traffic, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
In cancer, MIR3180-3 has been shown to regulate the delivery of various proteins to the plasma membrane, including cancer-associated antigens (CAATs), which are expressed in high levels in cancer cells. The regulation of CAATs delivery by MIR3180-3 has been shown to contribute to the development and progression of cancer.
MIR3180-3 has also been shown to play a role in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells, which is thought to be due to the dysfunction of various transmembrane proteins, including MIR3180-3.
In addition to its role in neurodegenerative diseases, MIR3180-3 has also been implicated in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the dysfunction of the immune system, which leads to the production of antibodies that can cause inflammation and damage to the body's tissues. MIR3180-3 has been shown to regulate the production and localization of antibodies, which may contribute to the development and progression of autoimmune disorders.
The potential utility of MIR3180-3 as a drug target or biomarker is its unique structure and subcellular localization, as well as its involvement in various cellular processes that are implicated in various diseases. Its regulation of ER protein traffic has been shown to contribute to the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.
In addition to its potential clinical applications, MIR3180-3 also has the potential to serve as a research tool for the study of various cellular processes, including protein folding, localization, and degradation. The structure and function of MIR3180-3 can be studied using various techniques, including biochemical, cellular, and mass spectrometry.
MIR3180-3 has also been shown to interact with various molecules, including transcription factors, DNA-binding proteins, and protein tyros. These interactions may have implications for the regulation of various cellular processes, including gene expression, DNA replication, and protein function.
In conclusion, MIR3180-3 is a potential drug target and biomarker for various diseases due to its unique structure and subcellular localization, as well as its involvement in the regulation of ER protein traffic and various cellular processes that are implicated in
Protein Name: MicroRNA 3180-3
The "MIR3180-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3180-3 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR3180-4 | MIR3180-5 | MIR3182 | MIR3183 | MIR3184 | MIR3185 | MIR3186 | MIR3187 | MIR3188 | MIR3189 | MIR3190 | MIR3191 | MIR3192 | MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665
